Peptide Therapy Guide: BPC-157, Sermorelin, and the 2026 Rules

Peptide therapy uses short chains of amino acids, the building blocks of proteins, to influence specific signals in the body, such as growth hormone release, tissue repair, or immune activity. A few peptides are FDA-approved drugs, but most wellness peptides offered today, including BPC-157 and CJC-1295 with ipamorelin, are compounded, not FDA-approved, and supported mainly by animal or small human studies. Their legal status shifted during 2026 and is still unsettled.

This guide is the starting point for StemVera's peptide therapy section. It explains what peptides are, where the rules stood as of late August 2026, how strong the evidence is for each popular peptide, what the real safety concerns are, why "research use only" vials are a bad idea, and what a clinician screens for before prescribing. It does not include dosing. Dosing decisions belong to your prescribing clinician.

What is peptide therapy?

Peptide therapy is the medical use of peptides, which are short strings of amino acids that act as chemical messengers. Many well-known medicines are peptides, including insulin and GLP-1 drugs like semaglutide. In wellness care, the term usually means compounded peptides prescribed off-label for goals like recovery, sleep, body composition, skin, or immune support.

It helps to sort peptides into two groups:

• FDA-approved peptide drugs. These went through clinical trials and FDA review for a specific use. Examples include insulin, semaglutide, tesamorelin (sold as Egrifta for a specific HIV-related condition), and bremelanotide (sold as Vyleesi for low sexual desire in premenopausal women).
• Compounded wellness peptides. These are prepared by a pharmacy for an individual prescription. They are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness, or quality before they reach patients. Most of the peptides people search for, like BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, and thymosin alpha-1, fall here.

Most peptides used in wellness care are given as small subcutaneous injections, meaning just under the skin. A few come as capsules, troches, nasal sprays, or creams.

Are peptides legal?

Peptides are legal to prescribe, but their compounding status is complicated and changed during 2026. As of August 27, 2026, the only FDA-approved products are branded drugs like tesamorelin. Popular wellness peptides are not FDA-approved, none has been added to FDA's list of approved compounding ingredients, and federal rules are still being decided.

How compounding rules apply to peptides

Under federal law, a traditional compounding pharmacy (called a 503A pharmacy) can generally only compound with a bulk ingredient if it has an official USP monograph, is part of an FDA-approved drug, or appears on a list the FDA creates through formal rulemaking. While that list is being built, the FDA sorts nominated ingredients into interim categories. Category 1 ingredients can be used while the FDA decides. Category 2 ingredients were flagged as raising significant safety concerns.

What changed in 2023 and 2024

• September 2023: The FDA placed many popular peptides, including BPC-157, in Category 2. For BPC-157, the agency cited possible immune reactions, peptide-related impurities, and little or no human safety information for the proposed routes.
• September 2024: AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, and selank came off Category 2 after their nominations were withdrawn, and the FDA then sent several of them for advisory committee review.
• October and December 2024: The FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin, CJC-1295, AOD-9604, and thymosin alpha-1 to the compounding list.

What changed in 2026

• April 2026: The FDA announced on April 15 that it would remove 12 more peptides from Category 2 after their nominations were withdrawn. The list included BPC-157, TB-500, MOTS-c, epitalon, DSIP (emideltide), semax, KPV, and injectable GHK-Cu. Removal did not make them approved compounding ingredients.
• July 2026: At a July 23 and 24 meeting, the advisory committee narrowly recommended adding BPC-157, TB-500, KPV, MOTS-c, epitalon, and semax to the compounding list and voted against DSIP. FDA staff reviewers had recommended against all seven, finding the available studies too small and short to establish safety or effectiveness.
• What it means: Committee votes are advisory. As of August 27, 2026, the FDA had not added any of these peptides to the list, which requires formal rulemaking. Injectable GHK-Cu and several others are scheduled for review before the end of February 2027.
• Enforcement: In August 2026, the FDA sent warning letters to online peptide sellers, stating that "research use only" labels did not change the fact that the products were marketed for people.

The practical takeaway: rules are in motion, and a licensed prescriber and pharmacy are responsible for following them. If anyone tells you a wellness peptide is "FDA-approved," be skeptical.

How strong is the evidence for peptide therapy?

It depends heavily on the peptide. Tesamorelin has solid clinical trial evidence for its approved use. Sermorelin was once an FDA-approved drug for children. Most other wellness peptides rest on animal research, lab studies, and small or short human trials, which is not enough to know how well they work or what long-term risks they carry.

The table below summarizes each peptide StemVera offers, how people commonly use it, our plain-language read of the evidence, its regulatory status as of August 27, 2026, and the format StemVera lists.

"Limited" does not mean "proven not to work." It means nobody can tell you with confidence how much it helps, who it helps, or what happens with long-term use. Anyone promising guaranteed healing, fat loss, or anti-aging results from these peptides is going beyond the science.

What are BPC-157 and TB-500 used for?

BPC-157 and TB-500 are mostly used for recovery goals, such as tendon, ligament, muscle, and gut healing. BPC-157 is a synthetic peptide studied mainly in animals, and TB-500 is a fragment of a natural protein called thymosin beta-4. Human evidence for both is thin, and both are banned in tested sports.

Here is what to know before considering either one:

• The research gap is real. FDA reviewers described the human BPC-157 studies they examined as short in duration, small in size, and not enough to establish safety or effectiveness.
• Quality matters more than usual. The FDA has flagged immune reactions and peptide impurities as concerns, which is why the source of the product matters.
• Athletes should skip them. International anti-doping authorities treat both as prohibited substances.
• They are not a substitute for diagnosis. A torn tendon, a stress fracture, or ongoing gut bleeding needs proper imaging, treatment, and sometimes surgery.

StemVera offers BPC-157 on its own and a BPC-157 and TB-500 blend, both as compounded injections prescribed off-label after clinician review.

What are sermorelin, CJC-1295, ipamorelin and tesamorelin?

These peptides prompt your pituitary gland to release more of your own growth hormone instead of supplying growth hormone directly. Sermorelin and tesamorelin mimic the natural hormone GHRH. CJC-1295 is a longer-acting GHRH analog, and ipamorelin works through a different growth hormone pathway. Because they raise growth hormone signaling, they need careful screening and monitoring.

Sermorelin

Sermorelin has the longest track record. It was FDA-approved as Geref for idiopathic growth hormone deficiency in children, and the manufacturer stopped selling it in 2008. The FDA later determined it was not withdrawn for safety or effectiveness reasons. Sermorelin used today for adults is compounded and prescribed off-label. See StemVera's sermorelin injection page for program details.

CJC-1295 and ipamorelin

Small studies in healthy adults found that CJC-1295 raised growth hormone and IGF-1 levels for days after an injection. Raising a lab number is not the same as proving a benefit for muscle, sleep, or aging, though, and the FDA advisory committee voted against adding either peptide to the compounding list in 2024. StemVera's CJC-1295 and ipamorelin combination is a compounded, off-label therapy.

Tesamorelin

Tesamorelin is the best-studied peptide in this group. As Egrifta, it is FDA-approved to reduce excess abdominal fat in adults with HIV who have lipodystrophy, and its labeling says it is not for weight loss. Labeling warnings include raised IGF-1, higher blood sugar, fluid retention, joint pain, and concerns for people with active cancer. StemVera's tesamorelin program is compounded, and uses outside the approved indication are off-label.

If your interest in these peptides is really about energy, libido, or muscle, it is worth checking hormones that have clearer testing and treatment paths. Our guide to how online TRT works explains testosterone testing. If you are losing weight on a GLP-1 and want to protect muscle, strength training and protein have the strongest evidence, as covered in our guide to preventing muscle loss on GLP-1s.

What about GHK-Cu, thymosin alpha-1 and other peptides?

GHK-Cu is a copper-binding peptide best known from skin-care products. Thymosin alpha-1 is an immune-signaling peptide with human trials in conditions like chronic hepatitis. DSIP, MOTS-c, and epitalon target sleep, metabolism, and aging. All are compounded and not FDA-approved, and none has strong evidence for the wellness goals people usually seek.

• GHK-Cu: Used for skin firmness, texture, and scalp support. Most research involves products applied to the skin, and data on injected GHK-Cu in people are limited. People with copper metabolism disorders, such as Wilson disease, need special caution.
• Thymosin alpha-1: Studied in people for chronic hepatitis B and C and as an immune add-on in other illnesses. It is not FDA-approved, and people with autoimmune disease, organ transplants, or immune-suppressing medicines need specialist-level review.
• DSIP: Marketed for sleep. Evidence is very limited, and the FDA advisory committee voted against it in July 2026. It should never delay testing for sleep apnea.
• MOTS-c and epitalon: Studied mostly in early and animal research for metabolism and aging. The July 2026 committee votes in their favor were close, and the FDA has not acted on them.

Is peptide therapy safe?

Peptide therapy can be reasonably well tolerated in the short term when a clinician screens carefully and a licensed pharmacy prepares the product, but long-term safety is largely unknown. Common issues include injection site reactions and flushing. Some peptides affect blood sugar, fluid balance, heart rate, or immune activity, and theoretical cancer concerns apply to growth hormone peptides.

Possible side effects

• Redness, itching, or a lump where you inject
• Flushing, warmth, headache, or lightheadedness
• A fast heartbeat or low blood pressure symptoms, reported with some growth hormone peptides
• Higher blood sugar, swelling, joint aches, or tingling hands with growth hormone signaling peptides
• Allergic or immune reactions, which can be serious

Get urgent care if you have

• Hives, swelling of the face or throat, or trouble breathing
• Chest pain, fainting, or a racing heartbeat that does not settle
• Fever, spreading redness, warmth, or pus at an injection site, which can mean infection
• Extreme thirst, frequent urination, or confusion, which can signal high blood sugar

Who peptide therapy is not for

• People who are pregnant, trying to conceive, or breastfeeding
• Anyone with active cancer, a recent cancer history, or an unexplained mass, especially for growth hormone peptides
• People with uncontrolled diabetes, pituitary disorders, or significant liver or kidney disease without specialist input
• Athletes who compete in tested sports
• Anyone under 18

Why should you avoid "research use only" peptides?

"Research use only" vials are sold without a prescription, a medical review, or the quality controls required of licensed pharmacies. You cannot confirm what is in the vial, how much, or whether it is sterile. The FDA has issued warning letters to sellers using this label, saying it does not change that the products target human use.

Gray-market peptides create risks that have nothing to do with the peptide itself:

• Wrong contents or strength. Without pharmacy oversight, mislabeling and contamination are real possibilities.
• No sterility assurance. Injecting a non-sterile product can cause serious infections.
• No screening. Nobody checks your medications, cancer history, or blood sugar before you start.
• No one to call. If something goes wrong, there is no prescriber or pharmacist responsible for your care.

The same rules for spotting legitimate online care apply to every treatment. Our guide on how to get treatment online safely lists the red flags to watch for.

What does a clinician screen for before prescribing peptides?

A careful clinician starts with your goals and health history, then checks for reasons a peptide could be unsafe: pregnancy, cancer history, diabetes, pituitary or hormone disorders, liver or kidney disease, immune conditions, allergies, and every medication you take. They may order labs, such as blood sugar or IGF-1, and they confirm whether you compete in tested sports.

A good screening conversation also covers:

• Whether a peptide is the right tool at all. Sleep problems may need a sleep study. Joint pain may need imaging or physical therapy. Fatigue may need thyroid, iron, or testosterone testing.
• Realistic expectations. What a meaningful change would look like and how long to give it before deciding to stop.
• The regulatory picture. That the product is compounded, not FDA-approved, and prescribed off-label.
• Follow-up. When to check in and which symptoms mean you should stop and call.

How to get started with peptide therapy through StemVera

Getting started with peptide therapy through StemVera happens online. You pick a peptide program, complete a short health questionnaire, and a licensed clinician reviews it, with a video visit when required. If treatment is appropriate, a licensed pharmacy ships it discreetly, and your care team stays available for follow-up and side effect questions.

1. Explore your options. Browse the peptides hub to compare programs such as BPC-157, CJC-1295 with ipamorelin, sermorelin, tesamorelin, GHK-Cu, the BPC-157 and TB-500 blend, and thymosin alpha-1.
2. Complete your health questionnaire. Share your goals, conditions, cancer history, allergies, and all medications and supplements.
3. Clinician review. A U.S.-licensed clinician decides whether a peptide is appropriate and which one fits. Some patients need a video visit or lab work first.
4. Pharmacy fulfillment. If prescribed, a licensed pharmacy prepares your medication and ships it with tracking.
5. Follow-up. Report side effects, ask questions, and let your care team know about any change in your health.

For costs, see current pricing on each treatment page, such as the BPC-157 page, since prices can change. Our how it works page explains each step in more detail.

Bottom line

Peptide therapy covers everything from FDA-approved drugs to compounded peptides with limited human evidence. As of August 2026, BPC-157 and most wellness peptides are not FDA-approved, and their legal status is still being decided. If you are curious, work with a licensed clinician and pharmacy, skip gray-market vials, and keep expectations realistic.